FDA Removes Expert with Ties to Eisai, Biogen from Leqembi Adcomm

Monday, the FDA removed neurologist David Weisman from an upcoming Peripheral and Central Nervous System Drugs Advisory Committee meeting to discuss the full approval of Eisai’s and Biogen’s Alzheimer’s disease medicine Leqembi (lecanemab).